R&D

October 8, 2015

The genomic landscape of response to EGFR blockade in colorectal cancer

Bertotti A, Papp E, Jones S, Adleff V, Anagnostou V, Lupo B, Sausen M, Phallen J, Hruban CA, Tokheim C, Niknafs N, Nesselbush M, Lytle K, Sassi F, Cottino F, Migliardi G, Zanella ER, Ribero D, Russolillo N, Mellano A, Muratore A, Paraluppi G, Salizzoni M, Marsoni S, Kragh M, Lantto J, Cassingena A, Li QK, Karchin R, Scharpf R, Sartore-Bianchi A, Siena S, Diaz LA Jr, Trusolino L, Velculescu VE.
Nature. 2015 Oct 8;526(7572):263-7
September 25, 2015

Pan-HER, an Antibody Mixture Simultaneously Targeting EGFR, HER2, and HER3, Effectively Overcomes Tumor Heterogeneity and Plasticity

Jacobsen HJ, Poulsen TT, Dahlman A, Kjær I, Koefoed K, Sen JW, Weilguny D, Bjerregaard B, Andersen CR, Horak ID, Pedersen MW, Kragh M, Lantto J.
Clin Cancer Res. 2015 Sep 15;21(18):4110-22.
July, 2015

A proof of concept trial of the anti-EGFR antibody mixture Sym004 in patients with squamous cell carcinoma of the head and neck.

Machiels JP1, Specenier P, Krauß J, Dietz A, Kaminsky MC, Lalami Y, Henke M, Keilholz U, Knecht R, Skartved NJ, Horak ID, Pamperin P, Braun S, Gauler TC.
Cancer Chemother Pharmacol. 2015 Jul;76(1):13-20
June, 2015

Safety and Activity of the First-in-Class Sym004 Anti-EGFR Antibody Mixture in Patients with Refractory Colorectal Cancer

Rodrigo Dienstmann, Amita Patnaik, Rocio Garcia-Carbonero, Andrés Cervantes, Marta Benavent, Susana Roselló, Bastiaan B.J. Tops, Rachel S. van der Post, Guillem Argilés, Niels J.Ø. Skartved, Ulla H. Hansen, Rikke Hald, Mikkel W. Pedersen, Michael Kragh, Ivan D. Horak, Stephan Braun, Eric Van Cutsem, Anthony W. Tolcher, and Josep Tabernero
Cancer Discov. 2015 Jun;5(6):598-609
June, 2015

Sym004: Truly a New Level of Anti-EGFR Treatment?

Stintzing, S and Heinemann, V.
Cancer Discov; 5(6); 578–80, 2015
January 22, 2015

Targeting Three Distinct HER2 Domains with a Recombinant Antibody Mixture Overcomes Trastuzumab Resistance

Pedersen MW, Jacobsen HJ, Koefoed K, Dahlman A, Kjær I, Poulsen TT, Meijer PJ, Nielsen LS, Horak ID, Lantto J, Kragh M.
Mol. Cancer Ther. Mar 2015
December, 2013

Sym004, a novel anti-EGFR antibody mixture, augments radiation response in human lung and head and neck cancers

Huang S, Peet CR, Saker J, Li C, Armstrong EA, Kragh M, Pedersen MW, Harari PM.
Mol Cancer Ther. 2013 Dec;12(12):2772-81
October, 2013

Sym004, a novel EGFR antibody mixture, can overcome acquired resistance to cetuximab

Iida M, Brand TM, Starr MM, Li C, Huppert EJ, Luthar N, Pedersen MW, Horak ID, Kragh M, Wheeler DL.
Neoplasia. 2013 Oct;15(10):1196-206